medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2009, Number 3

<< Back Next >>

Rev Mex Oftalmol 2009; 83 (3)

Alta frecuencia de hipertensión arterial en diabéticos con edema macular. ¿Intervenir sobre la angiotensina podría mejorar la eficacia de la fotocoagulación?

Razo-Blanco-Hernández DM, Vargas-Contreras EA, Lima-Gómez V

Language: Spanish
References: 22
Page: 167-170
PDF size: 103.05 Kb.


ABSTRACT

Background: Vascular endothelial growth factor (VEGF) enhanced in presence of angiotensin is among the factors that allow the persistence of clinically significant macular edema (CSME). We identified, in patients with CSME, the existence of high blood pressure (BP), which could increase the levels of VEGF by activating the renin-angiotensin axis.
Methods: An observational, analytic, cross sectional, prospective and open study was conducted. We evaluated diabetic patients with CSME with or without arterial hypertension (AH) diagnosis. The proportion and 95% confidence intervals (95% CI) that had systolic or diastolic BP that met the criteria of AH, according to the JNC 7, was identified in the sample and in patients with or without AH diagnosis.
Results: 54 patients, mean age 59.69 years, 50% had a diagnosis of AH. 88.88% of the patients with an AH diagnosis, and 74.07% who didn’t have it, presented systolic BP ›120 mmHg or diastolic BP ›80 mmHg. Altogether, 81.48% (IC 95% 71.12-91.84) of the patients had BP levels that met the criteria of AH.
Conclusions: Up to 91.84% of the patients with CSME could present high BP; in them, the activation of the reninangiotensin axis could delay the resolution of the retinal thickening, by increasing the VEGF.


REFERENCES

  1. Younis N, Soran H, Farook S. The prevention of type 2 diabetes mellitus: recent advances. QJM 2004; 97:451-455.

  2. Abuissa H, Jones PG, Marso SP y cols. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46:821-826.

  3. Cruz C. Panorama epidemiológico de la hipertensión arterial en México. Archivos de Cardiología de México 2001; 71:192-197.

  4. Norma Oficial Mexicana. NOM-030-SSA-2-1999 para la prevención, tratamiento y control de la presión arterial. Mexico; 2000.

  5. Hu G, Jousilahti P, Tuomilehto J. Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur Heart J 2007; 28:3059-3066.

  6. Deedwania PC. Hypertension and diabetes: new therapeutic options. Arch Intern Med 2000; 160:1585-1594.

  7. Chobanian AV, Bakris GL, Black HR y cols. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.

  8. Fong DS, Aiello L, Gardner TW y cols. Retinopathy in diabetes. Diabetes Care 2004; 27( Supl 1):S84-87.

  9. van Leiden HA, Dekker JM, Moll AC y cols. Risk factors for incident retinopathy in a diabetic and nondiabetic population: the HOORN study. Arch Ophthalmol 2003; 121:245-251.

  10. Klein R, Knudtson MD, Lee KE y cols. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twentyfive- year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008; 115:1859-1868.

  11. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26:2653-2664.

  12. Guan K, Hudson C, Wong T y cols. Retinal hemodynamics in early diabetic macular edema. Diabetes 2006; 55:813-818.

  13. Ryan SJ. Retina. St. Louis: Mosby-Yearbook; 2002.

  14. Funatsu H. Vitreous levels of vascular endothelial growth factor and intercelular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 2005; 112:806-816.

  15. Ishizaki E, Takai S, Ueki M y cols. Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol 2006; 141:129-134.

  16. Lima-Gómez V, Solorio-Smith R. Antecedente de Hipertensión arterial sistémica en pacientes diabéticos con y sin retinopatía. Rev Mex Oftalmol 2006; 80:78-82.

  17. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37:1053-1059.

  18. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98:766-785.

  19. Sandhu SS, Birch MK, Griffiths PG y cols. Short-term effects of focal argon laser treatment in diabetic maculopathy as demonstrated by optical coherence tomography. Retina 2007; 27:13-20.

  20. Flammer J, Mozaffarieh M. Autoregulation, a balancing actbetween supply and demand. Can J Ophthalmol 2008; 43:317-321.

  21. Morales MA, Carvajal CA, Ortiz E y cold. Regiones polimórficas del gen 11ß-hidroxiesteroide deshidrogenasa tipo 1 (11ßHSD1) en hipertensión arterial esencial: Posible rol etiopatogénico. Rev Med Chil 2008; 136:701-710.

  22. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000; 52:639-672.




2020     |     www.medigraphic.com